TRANSFER OF OBLIGATION Clause Samples
The Transfer of Obligation clause defines the conditions under which one party may assign or delegate its contractual duties to another party. Typically, this clause outlines whether such a transfer requires the consent of the other original party, and may specify exceptions or procedures for notification. Its core function is to ensure that all parties are aware of and agree to any changes in who is responsible for fulfilling contractual obligations, thereby preventing confusion or disputes over performance and accountability.
TRANSFER OF OBLIGATION. In accordance with Art. II.10, ▇▇▇▇ allows the BSP to transfer part or all of his aFRR Obligation to one or several Counterpart BSP(s). Similarly, the BSP may agree to make an additional aFRR Capacity available to ▇▇▇▇ as a result of a Transfer of Obligation from a Counterpart BSP to the BSP.
TRANSFER OF OBLIGATION. II.10.1 The BSP can transfer in day-ahead or in intraday, for a certain quarter-hour, part or all of its aFRR Obligation to one or several Counterpart BSP(s) holding a valid BSP Contract aFRR valid at least up to the date of the performance of the aFRR Obligation.
II.10.2 Similarly, the BSP may agree to make an additional quantity of aFRR Capacity available to ▇▇▇▇ as a result of a Transfer of Obligation from a Counterpart BSP to the BSP.
II.10.3 The BSP should at any time maintain its aFRR Obligation available to ELIA either by providing its aFRR Obligation by itself or by transferring part or all of its aFRR Obligation in accordance with Art. II.10.1.
II.10.4 The requestor party (being either the BSP or the Counterpart BSP) initiates the Transfer of Obligation. When the other party (being either the BSP or the Counterpart BSP) accepts the Transfer of Obligation, the status of the concerned Transfer of Obligation becomes accepted. The rules and procedure to be followed by the BSP and the Counterpart BSP in case of a Transfer of Obligation are described in Annex 8.
II.10.5 When the Transfer of Obligation presents a status accepted, as per Art. II.10.4, ▇▇▇▇ adapts the aFRR Obligation of the BSP and the Counterpart BSP for the applicable quarter-hour(s) by: • adding the volume transferred to the aFRR Obligation of the party taking over the aFRR Obligation; and • reducing by the volume transferred the aFRR Obligation of the party ceding the aFRR Obligation. The BSP and the Counterpart BSP undertake the necessary actions to provide the aFRR Service for the applicable quarter-hour(s) (without any action by ▇▇▇▇).
II.10.6 Consequently, the availability control, as per Art. II.14 and the activation control, as per Art. II.15, as well as the resulting incentives for non-compliance, as per Art. II.17, among other provisions, will be based on the amended aFRR Obligation of the BSP and the Counterpart BSP, resulting from the Transfer(s) of Obligation.
II.10.7 The remuneration for the aFRR Awarded, as per Art. II.16.3, remains fixed irrespective of any Transfer of Obligation that the BSP has agreed with Counterpart BSP(s).
II.10.8 ▇▇▇▇ does not grant any remuneration under Art. II.16.3 to the Counterpart BSP with which the BSP has agreed a Transfer of Obligation.
TRANSFER OF OBLIGATION. To the extent Business Associate is to carry out one or more of Covered Entity's obligation(s) under Subpart E of 45 C.F.R. Part 164, Business Associate must comply with the requirements of Subpart E that apply to the Covered Entity in the performance of such obligation(s);
TRANSFER OF OBLIGATION. See Work Statement NB-1 Attachment C. This Clinical Trial Agreement (“Agreement”) is entered into by and among CENTER FOR CLINICAL AND BASIC RESEARCH A/S, ▇▇▇▇▇▇▇▇▇▇▇ ▇, ▇, ▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ (“CCBR”) on behalf of itself and its ten [affiliated][controlled] Clinical Study Sites listed below and Nordic Bioscience A/S, ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇ (“Nordic Bioscience”), representing the interests of Radius Health, Inc. (“Sponsor”) concerning: Protocol No. BA058-05-003, “A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 (“Study Drug”) for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of Fracture” (together with any of its subsequent amendments, the “Protocol”), which will guide the performance of the Study, has been prepared by Radius and Nordic Bioscience and accepted by the Clinical Study Sites. CCBR has the legal authority to bind the following clinical study sites (the “Clinical Study Site(s)”):
TRANSFER OF OBLIGATION. In accordance with 21CFR Part 312, Subpart D (responsibilities of Sponsor) Transfer of Obligations needs to be in written format and if decided upon by the AstraZeneca clinical team also be agreed at a more detailed level through a separate “Roles and Responsibility” document to be included/reflected in any clinical study agreement with the study sites and/or the CRO or other clinical research providers contracted for the purpose of the Initial Studies.
TRANSFER OF OBLIGATION. In accordance with Section 7.2(i), Seller shall take all action that is necessary to transfer and assign the responsibility for the assumption of any obligation for contributions to the GCIU Fund (defined and described in Section 7.2(i)) that accrue on and after the Closing Date to the Buyer, including, but no limited to, executing any documents, and providing information to Buyer to effectuate the assignment and the administration of such responsibility to Buyer.
TRANSFER OF OBLIGATION. The covenants and conditions of this Lease shall be binding upon the heirs, legal representatives, successors and agreed assigns of any or all the Parties hereto.
TRANSFER OF OBLIGATION. The Option shall not be transferable by Option Holder except by his/her Last Will or the laws of the Holder's domicile at the time of his/her death relating to intestacy. During his/her lifetime, Option Holder is the only person who may exercise the Option. More specifically, without limiting the generality of the foregoing, the Option may not be assigned, transferred (except as permitted herein) pledged or hypothecated in any way, whether by operation of law or otherwise, and shall not be subject to execution, attachment or similar process. Any attempted assignment, transfer, pledge, hypothecation or other disposition of the Option contrary to the provisions hereof, and the levy of any attachment or similar process on the Option shall be null and void and without effect.
TRANSFER OF OBLIGATION. Neither of the Parties shall transfer or assign this Agreement, or any right or obligation hereunder (except the right to receive money) without the prior written consent of the other party, which consent shall not be unreasonably withheld. This Agreement shall inure to the benefit of and be binding upon the Parties hereto, their successors and permitted assigns. In no event shall Purchaser be allowed to transfer Credits or this Agreement for any use other than that identified in Purchaser’s Permit.
TRANSFER OF OBLIGATION. The Transferred Affordable Housing Obligation is hereby transferred to Village 8 East Owner’s Property. Village 8 East Owner shall satisfy the Village 3 Transferred Affordable Housing Obligation in connection with the development of Village 8 East Owner’s Property (the “Project”) as described below.